Vast has opened their Reg CF public funding round

Invest now

Chronic lung disease is a vast problem. We’ve made it our problem.

Breathing is Fundamental

500M individuals worldwide suffer from a chronic lung disease

At Vast Therapeutics, we are developing breakthrough medicines to treat chronic respiratory diseases so that patients can get back to shopping with friends. Back to walking the dog. Back to playing with their children or grandchildren. Back to traveling the world.
BACK TO LIVING

Learn More
Grandparents running on the beach with their grandchildren

Press Releases

Pipeline

Bronchiectasis

Lead Optimization

Preclinical

Phase 1

Phase 2

Phase 3

Cystic Fibrosis

Non-CF Bronchiectasis

Other Respiratory

Lead Optimization

Preclinical

Phase 1

Phase 2

Phase 3

NTM Disease

COPD

Disease Populations

Chronic lung diseases worsen over time due to a harmful cycle of inflammation and infection. This can lead to difficulty breathing, frequent hospital stays, and perpetual decline in quality of life. Our mission is to develop breakthrough therapies that address the root causes of these debilitating conditions and reshape the future of respiratory medicine.